These results suggest that serum TARC, IL-22, and IgE levels and epidermal thickness are itch-related events associated with dupilumab, and also that serum IL-31 levels may reflect the degree of IENF density in patients with AD. The gene discussed is CCL17; the disease is Alzheimer disease.